24666-61-3

Usage

Molecular weight

335.39 g/mol

Structure

2-(((benzyloxy)carbonyl)amino)-4-((tert-butoxycarbonyl)amno)butanoic acid

Protecting groups

Benzyloxy and tert-butoxycarbonyl (Boc) groups attached to the amino group and carboxyl group, respectively

Function

Protects the amino group during peptide synthesis, preventing unwanted side reactions

Use

Building block for the synthesis of larger peptides and proteins, commonly used in biochemistry and drug discovery

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 3309-41-9 N-(benzyloxycarbonyl)-3-cyano-L-alanine 
• 2304-96-3 N-benzyloxycarbonyl-L-asparagine 

Relevant academic research and scientific papers

Hydroxypyridinone-diamine hybrids as potential neuroprotective agents in the PC12 cell-line model of alzheimer's disease

There is an urgent need to propose effective treatments for Alzheimer’s disease (AD). Although the origin of the disease is poorly understood, several therapeutic options have been proposed. The new therapeutic approaches targeting biometal-mediated neurodegenerative pathways appear to be interesting ones. As a continuation of our preceding studies, two novel series of advanced glycation endproducts (AGE)/advanced lipid peroxidation endproducts (ALE) inhibitors have been developed as multifunctional scavengers. This extended work allowed us to highlight the new hydroxypyridinone-diamine hybrid IIa-3 bearing a C4 alkyl linker between the two pharmacophores. This derivative exhibited preserved potent capacities to trap reactive carbonyl species (vicinal diamine function) as well as reactive oxygen species and transition metals (hydroxypyridinone moiety) in comparison with previously described lead compound 1. In addition, its good predicted absorption, distribution, metabolism and excretion (ADME) properties were correlated with a better efficacy to inhibit in vitro methylglyoxal-induced apoptosis in neuronal-like PC12 cells. This new promising agent revealed improved druglikeness and ability to prevent biometal-mediated oxidative and carbonyl stress amplification involved in AD pathogenesis.

Aminoethylglycine containing polypeptides

Novel somatostatin analogues containing one or more aminoethylglycyl residues at the amino and/or carboxyl terminus or in the ring position are described. The compounds are potent and long lasting inhibitors of gastric acid secretion.